Dr Mario Sznol talks to ecancer at ASCO 2013 about long-term follow-up results from an expanded phase I study examining the effects of nivolumab in advanced melanoma. 107 patients were treated with five different doses of nivolumab. All patients had disease that worsened despite prior standard systemic therapies — 25 percent had three or more prior therapies and 63 percent had two or more. Overall, 33 out of 107 (31 percent) of patients experienced tumor shrinkage of at least 30 percent and responses were seen at all doses. The estimate for survival at two years was 43 percent. The median overall survival across all doses was 16.8 months; 20.3 months for the dose chosen for study in subsequent clinical trials.